LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Inicio・Lista de Acciones・CytoSorbents Corp

CytoSorbents Corp

Cerrado

SectorSanidad

0.44 2.33

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.43

Máximo

0.45

Métricas clave
By Trading Economics
Ingresos	368K -5.1M
Ventas	-370K 8.9M
BPA	-0.08
Margen de beneficios	-57.863
Empleados	129
EBITDA	648K -3M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+63.04% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-9.5M 30M
Apertura anterior	-1.89
Cierre anterior	0.44

Noticias sobre sentimiento de mercado

By Acuity

46%

54%

135 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

0.705 / 0.771 Soporte y Resistencia

CytoSorbents Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 may 2026, 22:48 UTC

Adquisiciones, fusiones, absorciones

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 may 2026, 16:49 UTC

Ganancias

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 may 2026, 16:26 UTC

Principales Movimientos del Mercado

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 may 2026, 23:51 UTC

Charlas de Mercado

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 may 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 may 2026, 23:30 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 may 2026, 23:30 UTC

Charlas de Mercado

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 may 2026, 22:33 UTC

Adquisiciones, fusiones, absorciones

Conduent to Sell Public Transit Business to Modaxo for $164M

21 may 2026, 21:53 UTC

Ganancias

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 may 2026, 21:02 UTC

Ganancias

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 may 2026, 20:55 UTC

Ganancias

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 may 2026, 20:30 UTC

Acciones populares

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 may 2026, 20:20 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 may 2026, 20:20 UTC

Charlas de Mercado

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 may 2026, 20:20 UTC

Ganancias

Webull 1Q Adj EPS 3c >BULL

21 may 2026, 20:20 UTC

Ganancias

Webull 1Q Rev $159.9M >BULL

21 may 2026, 20:18 UTC

Charlas de Mercado

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 may 2026, 20:18 UTC

Ganancias

Webull 1Q Loss/Shr 4c

21 may 2026, 19:43 UTC

Charlas de Mercado

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 may 2026, 18:58 UTC

Ganancias

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 may 2026, 18:15 UTC

Charlas de Mercado

Gold Higher For Second Consecutive Day -- Market Talk

21 may 2026, 17:40 UTC

Charlas de Mercado

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 may 2026, 17:04 UTC

Charlas de Mercado

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 may 2026, 17:01 UTC

Ganancias

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 may 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Stellantis Targets Distant but Constructive -- Market Talk

21 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

Comparación entre iguales

Cambio de precio

CytoSorbents Corp previsión

Precio Objetivo

By TipRanks

63.04% repunte

Estimación a 12 Meses

Media 0.75 USD 63.04%

Máximo 0.75 USD

Mínimo 0.75 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CytoSorbents Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para CytoSorbents Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.705 / 0.771Soporte y Resistencia

All events are bearish.

Sentimiento

By Acuity

135 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.